References
- 1. Jabbour A, Macdonald P. Latest Developments in Heart Transplantation: A Review. Clinical Therapeutics. 2015;37:2234-2241.10.1016/j.clinthera.2015.08.019
- 2. Salyer J, Flattery MP, Joyner PL, et al. Lifestyle and quality of life in long-term cardiac transplant recipients. J Heart Lung Transplant. 2003;22:309-321.10.1016/S1053-2498(02)00552-1
- 3. Sánchez-Enrique C, Jorde UP, González-Costello J. Heart Transplant and Mechanical Circulatory Support in Patients with Advanced Heart Failure. Rev Esp Cardiol. 2017;70:371-381.10.1016/j.recesp.2016.10.032
- 4. Avram R, Laicu S, Ciocârlie T, et al. Clinical and therapeutical particularities of heart failure in elderly. Romanian Journal of Cardiology. 2014;suppl:236-237.
- 5. López-Sendón J. The heart failure epidemic. Medicographia. 2011;33:363-369.
- 6. Merlo M, Caiffa T, Gobbo M, Adamo L, Sinagra G. Reverse remodeling in Dilated Cardiomyopathy: Insights and future perspectives. IJC Heart & Vasculature. 2018;18:52-57.10.1016/j.ijcha.2018.02.005598848529876504
- 7. Carmona M, García-Olmos LM, Alberquilla A, et al. Heart failure in the family practice: a study of the prevalence and co-morbidity. Fam Pract. 2011;28:128-133.10.1093/fampra/cmq08420978242
- 8. Kong G, Xu DL, Body R, Yang JB, Mackway-Jones K, Carley S. A belief rule-based decision support system for clinical risk assessment of cardiac chest pain. Eur J Oper Res. 2012;219:564-573.10.1016/j.ejor.2011.10.044
- 9. Dag A, Oztekin A, Yucel A, Bulur S, Megahed FM. Predicting heart transplantation outcomes through data analytics. Decision Support Systems. 2017;94:42-52.10.1016/j.dss.2016.10.005
- 10. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J Heart Lung Transplant. 2004;23:S187-S193.10.1016/j.healun.2004.03.00915093804
- 11. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149:168-174.10.1016/j.ahj.2004.07.00515660049
- 12. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant. 2006;25:434-439.10.1016/j.healun.2005.11.45216563974
- 13. Lemaitre F, Antignac M, Fernandez C. Monitoring of tacrolimus concentrations in peripheral blood mononuclear cells: application to cardiac transplant recipients. Clinical Biochemistry. 2013;46:1538-1541.10.1016/j.clinbiochem.2013.02.01123454394
- 14. Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant. 2005;24:517-525.10.1016/j.healun.2005.02.00215896747
- 15. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. American Journal of Transplantation. 2006;6:1377-1386.10.1111/j.1600-6143.2006.01290.x16686761
- 16. Cozzi S, Martini A, Menestrina N, Gazzani S, Schweiger V, Gottin L. Analysis of risk and prognostic factors of mortality in post-transplant patients in the intensive care unit. Crit Care. 2005;9:P234.10.1186/cc3297